Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P51460

UPID:
INSL3_HUMAN

ALTERNATIVE NAMES:
Leydig insulin-like peptide; Relaxin-like factor

ALTERNATIVE UPACC:
P51460; B4DZ72; G3XAG0; Q3KPI5; Q3KPI6; Q6YNB5; Q9UEA2; Q9UPH6

BACKGROUND:
The protein Insulin-like 3, known alternatively as Leydig insulin-like peptide or Relaxin-like factor, is vital for testicular function and development. It serves as a ligand for the LGR8 receptor, indicating its significant role in the process of testicular descent in the fetal stage, as denoted by its gene's accession number P51460.

THERAPEUTIC SIGNIFICANCE:
Insulin-like 3's involvement in Cryptorchidism, a prevalent congenital disorder leading to increased risks of infertility and testicular cancer, underscores its therapeutic potential. Exploring the functions of Insulin-like 3 could pave the way for innovative treatments for these reproductive challenges.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.